AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17928994 — intervention group
Group type: COMPARATOR
Intervention: Moderate glucose control group (MGC) with a blood glucose target of 6-8 mmol/l
Number of subjects: 90
Study 17928994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality by day 30
Number of subjects: 90
Study 15011890 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 50
Study 15011890 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 50
Study 11724204 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 145
Study 11724204 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg)
Number of subjects: 145
Study 9425876 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Valproic Acid USP (Solvay)
Number of subjects: 64
Study 9425876 — intervention group
Group type: COMPARATOR
Intervention: Depakene
Number of subjects: 64
Study 8488960 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015-0.025 mg/kg haloperidol
Number of subjects: 16
Study 8488960 — intervention group
Group type: COMPARATOR
Intervention: 2 ml normal saline (control)
Number of subjects: 16
Study 3318435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 mg at bedtime)
Number of subjects: 40
Study 3318435 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 40
Study 3318435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 40
Study 3318435 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 40
Study 29345541 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld full water bottle (FULL; 16.9 fluid oz; 454 g)
Number of subjects: 42
Study 29345541 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld half-full water bottle (HALF; 8.4 fluid oz; 227 g)
Number of subjects: 42
Study 29345541 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-worn bottle belt holder (BELT; hydration belt; 676 g)
Number of subjects: 42
Study 29345541 — intervention group
Group type: COMPARATOR
Intervention: Control run (CON)
Number of subjects: 42
Study 25849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test (WT) with 8.7% of body mass (BM)
Number of subjects: 20
Study 25849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test (WT) with 11% of body mass (BM)
Number of subjects: 20
Study 25849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-Velocity test (FVT)
Number of subjects: 20
Study 25849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test (WT)
Number of subjects: 20
Study 25887136 — intervention group
Group type: EXPERIMENTAL
Intervention: BT086 (IgM-enriched immunoglobulin preparation)
Number of subjects: 0
Study 25887136 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 0
Study 24006952 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer (GAT)
Number of subjects: 36
Study 24006952 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare PRO (ICP)
Number of subjects: 36
Study 24006952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen AVIA (TPA)
Number of subjects: 36
Study 21586215 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive oral hygiene devices and orofacial exercise
Number of subjects: 48
Study 21586215 — intervention group
Group type: COMPARATOR
Intervention: Usual dental care (manual toothbrush and dental floss)
Number of subjects: 48
Study 18508140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 415
Study 18508140 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (not explicitly mentioned as control)
Number of subjects: 415
Study 17942271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical breast cancer risk above average
Number of subjects: 249
Study 15234486 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional instability of the ankle joint
Number of subjects: 24
Study 15234486 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 11566651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (EF)
Number of subjects: 474
Study 11566651 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed
Number of subjects: 474
Study 11566651 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (TF)
Number of subjects: 474
Study 9597051 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute scripted informational intervention
Number of subjects: 0
Study 9597051 — intervention group
Group type: COMPARATOR
Intervention: Uninformed patients
Number of subjects: 0
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg + PG05 1 mg on the 3rd or 4th day
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg b.i.d. (total amount of 150mg) + PG05 1mg on the 3rd or 4th day
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg b.i.d. (total amount of 125mg) + PG05 1mg in the morning of the 3rd day
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200mg + misoprostol 600 micrograms on the 3rd day
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 150mg + misoprostol 600 micrograms on the 3rd day
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg immediately, then 25 mg b.i.d. (total amount of 150mg) + misoprostol 600 micrograms
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg in the morning and 25mg in the evening for two days (total amount of 150 mg) + misoprostol 600 micrograms
Number of subjects: 1035
Study 7750407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg b.i.d. (total amount of 125mg) + misoprostol 400 micrograms
Number of subjects: 1035
Study 2223363 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 300 ml h‐1
Number of subjects: 60
Study 2223363 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 600 ml h‐1
Number of subjects: 60
Study 2223363 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 1200 ml h‐1
Number of subjects: 60
Study 345827 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (pyridoxine)
Number of subjects: 16
Study 345827 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 16
Study 31524502 — intervention group
Group type: EXPERIMENTAL
Intervention: Taichi exercise for 24 weeks
Number of subjects: 92
Study 31524502 — intervention group
Group type: COMPARATOR
Intervention: Health education lectures (Control)
Number of subjects: 92
Study 30957736 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 33
Study 30957736 — intervention group
Group type: COMPARATOR
Intervention: Present-Centred Therapy (PCT)
Number of subjects: 33
Study 28731611 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink consumption
Number of subjects: 919
Study 28731611 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep patterns
Number of subjects: 919
Study 25710288 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 582
Study 25710288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART height-for-age Z-score
Number of subjects: 582
Study 25710288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART BMI-for-age in girls
Number of subjects: 582
Study 25710288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanner stage 5
Number of subjects: 582
Study 26658902 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 132
Study 26658902 — intervention group
Group type: COMPARATOR
Intervention: PCV10
Number of subjects: 132
Study 23895801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (target dose 15-20 mg/wk)
Number of subjects: 7000
Study 23895801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study 21649614 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms (endorsed by 12% of participants, 2,041/17,205)
Number of subjects: 17205
Study 21649614 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD all clusters
Number of subjects: 17205
Study 21649614 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial PTSD
Number of subjects: 17205
Study 21649614 — intervention group
Group type: COMPARATOR
Intervention: No trauma history or trauma but no symptoms
Number of subjects: 17205
Study 19032751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity program for flexed posture
Number of subjects: 0
Study 19032751 — intervention group
Group type: COMPARATOR
Intervention: Non-specific physical activity protocol for the elderly
Number of subjects: 0
Study 16244087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg twice daily
Number of subjects: 0
Study 16244087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16244087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) strategy
Number of subjects: 0
Study 15013268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment (300 mg loading dose 24 hours before PCI)
Number of subjects: 20
Study 15013268 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel pretreatment (control group)
Number of subjects: 20
Study 10764368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone consultation
Number of subjects: 97000
Study 10374272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine treatment group
Number of subjects: 3064
Study 10374272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3064
Study 7939508 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuit with a 50% reduction of the standard heparin dose
Number of subjects: 19
Study 7939508 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB circuit with a standard heparin dose (300 IU/kg)
Number of subjects: 19
Study 3064861 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered to 188 patients
Number of subjects: 376
Study 3064861 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (64 Gy) or pre-operative radiotherapy (44 Gy)
Number of subjects: 376
Study 3064861 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + radiotherapy
Number of subjects: 376
Study 3064861 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy
Number of subjects: 376
Study 29458335 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated children's care clinic (ICCC)
Number of subjects: 112
Study 29458335 — intervention group
Group type: COMPARATOR
Intervention: Self-directed care pathway
Number of subjects: 112
Study 26920669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided forearm block with saline placebo wrist block
Number of subjects: 12
Study 26920669 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark-based wrist block with saline placebo ultrasound-guided forearm block
Number of subjects: 12
Study 26920669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided forearm block
Number of subjects: 12
Study 25764615 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath series 5 videolaryngoscope (MGL)
Number of subjects: 22
Study 25764615 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 22
Study 23444203 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical Negative Pressure (ANP) irrigation
Number of subjects: 32
Study 23444203 — intervention group
Group type: COMPARATOR
Intervention: Positive Pressure (PP) irrigation
Number of subjects: 32
Study 20059360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp (80 mU/m(2) per min)
Number of subjects: 33
Study 20059360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp
Number of subjects: 33
Study 18173766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional clostridial collagenase injection therapy (10,000 units, 0.25 cm³ per injection, administered over 7-10 days, with a repeat treatment at 3 months)
Number of subjects: 25
Study 16423441 — intervention group
Group type: EXPERIMENTAL
Intervention: Real patient assessments with radiographic information
Number of subjects: 201
Study 16423441 — intervention group
Group type: COMPARATOR
Intervention: Paper patient assessments without radiographic information
Number of subjects: 201
Study 16423441 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 clinical assessment
Number of subjects: 201
Study 16423441 — intervention group
Group type: COMPARATOR
Intervention: Group 4 clinical assessment
Number of subjects: 201
Study 14699304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg) and 600 mg calcium per day for 2 years
Number of subjects: 38
Study 14699304 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 600 mg calcium per day for 2 years
Number of subjects: 38
Study 11038976 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified recipe of Wang Kentang's Bai Fu Ling Wan
Number of subjects: 32
Study 11038976 — intervention group
Group type: COMPARATOR
Intervention: Capoton (control group)
Number of subjects: 32
Study 8837183 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA) with 3 mL of hyperbaric 0.5% bupivacaine
Number of subjects: 60
Study 8837183 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 60
Study 8837183 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) maintained with isoflurane and nitrous oxide
Number of subjects: 60
Study 8837183 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 60
Study 7840600 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin
Number of subjects: 10
Study 7840600 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of ofloxacin plus 11 g of colloidal aluminum phosphate
Number of subjects: 10
Study 3224543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual decision making
Number of subjects: 34
Study 3224543 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic
Number of subjects: 34
Study 3224543 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritarian
Number of subjects: 34
Study 3224543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 29246848 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for IDH
Number of subjects: 803
Study 26129915 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bout group (N=16) performed 2 bouts of sport-specific sprints separated by 14 days.
Number of subjects: 32
Study 26129915 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=16) performed a single bout of the same sprint protocol.
Number of subjects: 32
Study 26129915 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bout group (N=16)
Number of subjects: 32
Study 25636253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 50
Study 25636253 — intervention group
Group type: COMPARATOR
Intervention: 90° side‐lying position
Number of subjects: 50
Study 25636253 — intervention group
Group type: COMPARATOR
Intervention: 60° side‐lying position
Number of subjects: 50
Study 23388114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal peer support (RPS)
Number of subjects: 0
Study 23388114 — intervention group
Group type: COMPARATOR
Intervention: Nurse care management
Number of subjects: 0
Study 20620208 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 0
Study 20620208 — intervention group
Group type: COMPARATOR
Intervention: Home exercise training
Number of subjects: 0
Study 18423050 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive small group education program with locally adapted guidelines (Group 1)
Number of subjects: 51
Study 18423050 — intervention group
Group type: COMPARATOR
Intervention: Adapted guidelines only (Group 2)
Number of subjects: 51
Study 18423050 — intervention group
Group type: COMPARATOR
Intervention: Unrelated education intervention (Group 3)
Number of subjects: 51
Study 16622162 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system
Number of subjects: 4507
Study 16622162 — intervention group
Group type: COMPARATOR
Intervention: No computerized clinical decision support system (control)
Number of subjects: 4507
Study 12531808 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 412
Study 12531808 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation without G-CSF
Number of subjects: 412
Study 12531808 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus G-CSF
Number of subjects: 412
Study 12531808 — intervention group
Group type: COMPARATOR
Intervention: Neither irradiation nor G-CSF
Number of subjects: 412
Study 12531808 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (excluding irradiation)
Number of subjects: 412
Study 11049883 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 11049883 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 10
Study 11049883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8969721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate infusion, 25 mg/kg (maximum, 2 gm) for 20 minutes
Number of subjects: 31
Study 8969721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivolume saline solution for 20 minutes)
Number of subjects: 31
Study 8443401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day
Number of subjects: 257
Study 8443401 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate (MPA) 500 mg twice a day
Number of subjects: 257
Study 6391658 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus immunotherapy with PSK
Number of subjects: 73
Study 6391658 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 73
Study 31241761 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 50
Study 31241761 — intervention group
Group type: COMPARATOR
Intervention: Control group (live implant insertions)
Number of subjects: 50
Study 28889787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 24
Study 28889787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic appliances)
Number of subjects: 24
Study 27718784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 361
Study 27718784 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (methotrexate, docetaxel, or cetuximab)
Number of subjects: 361
Study 22238398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusions of glucose at 1, 2, or 3 kcal/min for 60 minutes
Number of subjects: 24
Study 19962342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin plus supportive treatment (Group A, n=64)
Number of subjects: 136
Study 19962342 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment only (Group B, n=72)
Number of subjects: 136
Study 17506865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (20, 40, and 60 kPa transcutaneous oxygen tensions)
Number of subjects: 9
Study 16298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (group 1)
Number of subjects: 298
Study 16298651 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose for 2 doses (group 2)
Number of subjects: 298
Study 16298651 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction (group 3)
Number of subjects: 298
Study 16298651 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 298
Study 12065558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,250 mg/m² twice daily on days 1 to 14 plus docetaxel 75 mg/m² on day 1
Number of subjects: 511
Study 12065558 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m² on day 1
Number of subjects: 511
Study 12065558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511
Study 12065558 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 511
Study 10219640 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 61
Study 10219640 — intervention group
Group type: COMPARATOR
Intervention: Octenidine hydrochloride
Number of subjects: 61
Study 7611158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1.2 g/day) and lovastatin (20 mg/day)
Number of subjects: 0
Study 7611158 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0
Study 7611158 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid (1.2 g/day)
Number of subjects: 0
Study 7611158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nicotinic acid and lovastatin
Number of subjects: 0
Study 7611158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid and lovastatin combination
Number of subjects: 0
Study 2775618 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside dosage based on pharmacokinetic analysis
Number of subjects: 0
Study 389175 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 units of equine tetanus antitoxin (TAT), intravenously and intramuscularly
Number of subjects: 60
Study 389175 — intervention group
Group type: COMPARATOR
Intervention: 40,000 units TAT, IV and IM, plus 150 units of human tetanus immune globulin (TIG) intrathecally
Number of subjects: 60
Study 30693821 — intervention group
Group type: EXPERIMENTAL
Intervention: Idioms
Number of subjects: 0
Study 30693821 — intervention group
Group type: EXPERIMENTAL
Intervention: Binomials
Number of subjects: 0
Study 30693821 — intervention group
Group type: EXPERIMENTAL
Intervention: Collocations
Number of subjects: 0
Study 30693821 — intervention group
Group type: COMPARATOR
Intervention: Control phrases
Number of subjects: 0